Read more
15:41 · 7 June 2021

Biogen trading paused after company received approval for its Alzheimer's drug

-
-
Open account Download free app

Biogen (BIIB.US) stock has been halted  after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.

Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5

4 March 2026, 16:56

📀Coinbase and MicroStrategy surge as Trump challenges Wall Street banks

4 March 2026, 16:08

US OPEN: Wall Street buoyed by robust data and shifting sentiment

4 March 2026, 13:44

Navigating Middle East uncertainty and tariff risks

4 March 2026, 12:34

Market wrap: European and US stocks try to rebound rebound 📈

This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.

Join over 2 Million investors from around the world